Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com
This article announces the filing of Form 144 for IRONWOOD PHARMACEUTICALS INC on September 27. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider transactions. The brief report provides no further details beyond the company name and filing date.
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com
This article announces the filing of Form 144 for IRONWOOD PHARMACEUTICALS INC on September 27. Form 144 is a notice of the intent to sell restricted securities. The brief notice was published by Investing.com.
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com
The article is a Form 144 filing for IRONWOOD PHARMACEUTICALS INC, dated September 27. It simply states the company name and the date of the filing, without providing further details about the content of the form. This type of filing typically indicates an intent to sell restricted or controlled securities.
Form 144 IRONWOOD PHARMACEUTICALS INC For: 27 September By Investing.com
This article announces a Form 144 filing for IRONWOOD PHARMACEUTICALS INC (IRWD) on September 27. A Form 144 is a notice of the intent to sell restricted securities, and the article provides this specific filing date without further details on the transaction itself.
83,306 shares to cover taxes: Ironwood Pharmaceuticals (IRWD) ex-officer proposes a sale
A former officer of Ironwood Pharmaceuticals (IRWD), Michael Shetzline, has proposed selling 83,306 Class A common shares valued at approximately $377,376.18. This sale is intended to cover taxes associated with the vesting of stock awards. The transaction is scheduled for September 24, 2026, and is being handled through E Trade Securities LLC.
Ironwood Pharmaceuticals Director Alexander J. Denner Awarded 3,694 Shares Under Compensation Policy
Alexander J. Denner, a director at Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD), was awarded 3,694 shares of Class A Common Stock on September 15, 2026. This award was part of the company's non-employee director compensation plan and was acquired at no cost. Following this transaction, Denner's direct beneficial ownership in the company now totals 327,549 shares.
IRWD Stock Price, Quote & News
This article provides an overview of Ironwood Pharmaceuticals, Inc. (IRWD) stock, including its current trading price, market capitalization, P/E ratio, and 52-week range. It also lists recent news and earnings updates related to the company, such as FDA approval for Linzess and Q1 financial results. The company, founded in 1998, specializes in developing GI products and does not currently pay dividends.
Ironwood Pharmaceuticals Inc. Class A (IRWD) Shareholding Pattern – Promoters, FIIs & DIIs
This article details the shareholding pattern of Ironwood Pharmaceuticals Inc. Class A (IRWD), listing key institutional shareholders and their percentage of equity and changes over various filing dates up to March 31, 2023. It also provides recent insider trading activities, showing several sell transactions in February and November 2024. The stock data includes current price, market cap, revenue, and valuation ratios.
Armistice Capital (IRWD) discloses 13.9M-share Ironwood Pharmaceuticals stake
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 13,932,000 shares of Ironwood Pharmaceuticals, Inc.'s Class A common stock, which represents 8.43% of the outstanding class as of June 30, 2026. This stake is held by Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager, holding shared voting and dispositive power. Steven Boyd, as the managing member of Armistice Capital, is also considered a beneficial owner.
State Street Corporation (NYSE: IRWD caretaker) holds 5.4% of Ironwood common stock
State Street Corporation has disclosed a 5.4% stake in Ironwood Pharmaceuticals common stock through a passive Schedule 13G filing. The investment manager beneficially owns 8,809,601 shares, primarily with shared voting and dispositive power through its subsidiaries. This significant ownership makes State Street a key institutional holder in Ironwood.
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
Ironwood Pharmaceuticals reported strong second-quarter 2026 results, leading the company to raise its full-year financial guidance for LINZESS U.S. net sales, total revenue, and adjusted EBITDA. The company also announced the initiation of the confirmatory Phase 3 STARS-2 trial for apraglutide in short bowel syndrome with intestinal failure (SBS-IF), aiming for it to be the first long-acting GLP-2 analog on the market. These achievements are attributed to strong LINZESS performance, including improved net price and prescription demand growth, and strategic advancements in its pipeline.
BlackRock, Inc. (NASDAQ: IRWD) discloses 8.1% beneficial stake in Ironwood
BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.1% beneficial ownership stake in Ironwood Pharmaceuticals Inc, totaling 13,373,568 shares of Class A stock. BlackRock exercises sole voting power over 13,195,313 shares and sole dispositive power over all 13,373,568 shares. The filing specifies that while various clients may benefit from dividends or sale proceeds, no individual client's interest exceeds five percent of Ironwood's outstanding common shares.
Return on assets % of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76
The article provides financial data specifically focusing on the Return on Assets (%) for Ironwood Pharmaceuticals, Inc. Class A, traded under the symbol I76 on the Hamburg Stock Exchange. It indicates historical values and changes for this metric, noting that the market is currently closed with no trades.
Total operating expenses of Ironwood Pharmaceuticals, Inc. Class A – HAM:I76
This article states the total operating expenses for Ironwood Pharmaceuticals, Inc. Class A, traded on the Hamburg Stock Exchange under the ticker I76. It indicates that the market is closed with no current trades. Further financial details would be available in a dedicated "Financials" section not fully displayed here.
Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – BX:I76
Ironwood Pharmaceuticals, Inc. Class A (I76 BX Swiss) generated 234.78 million CHF last year, primarily from its Human Therapeutics segment. This represents a decrease from the previous year's 319.15 million CHF. The United States was the largest contributor to revenue, accounting for 229.38 million CHF.
Ironwood Pharmaceuticals, Inc. Class A Revenue Breakdown – SWB:I76
Ironwood Pharmaceuticals, Inc. (SWB:I76) generated €252.15 million in revenue last year, primarily from its Human Therapeutics segment. This marks a decrease from the previous year's €339.45 million, with the United States contributing the majority of the revenue.
Ironwood Pharmaceuticals (IRWD) grants 137,036-share RSU new-hire award to CMO
Ironwood Pharmaceuticals Inc. (IRWD) has granted its SVP, CMO, and Head of Research & Drug Development, Jeffrey Silber, a new-hire restricted stock unit (RSU) award covering 137,036 shares of Class A Common Stock. This award vests 25% annually over four years and was issued at a grant price of US$0.00 per share. This RSU grant is part of Silber's compensation package and aligns his interests with the company's long-term growth.
Ronald Silver, PFO, sells $578k in Ironwood Pharma stock
Ronald Silver, Principal Financial Officer at Ironwood Pharmaceuticals (NASDAQ:IRWD), sold 127,890 shares of Class A Common Stock for over $578,000. This sale was part of a pre-planned trading strategy, and Mr. Silver still directly owns 313,680 shares. The transaction occurred after a significant 493% surge in IRWD shares over the past year and recent positive financial performance by the company.
Ronald Silver, PFO, sells $578k in Ironwood Pharma stock By Investing.com
Ronald Silver, Principal Financial Officer of Ironwood Pharmaceuticals (NASDAQ:IRWD), sold 127,890 shares of Class A Common Stock for $578,062. This sale, executed via a Rule 10b5-1 trading plan, leaves him with 313,680 shares. The transaction follows recent strong financial results for Ironwood, including outperforming Q1 2026 earnings and revenue estimates, and FDA approval for Linzess in younger children, despite a pre-market stock decline.
Ironwood (IRWD) finance chief sells 127,890 shares in 10b5-1 stock plan
Ronald Silver, Ironwood Pharmaceuticals' Principal Financial and Accounting Officer, sold 127,890 shares of Class A common stock at a weighted average price of $4.52 per share under a pre-arranged Rule 10b5-1 trading plan. Despite this sale, Silver retains a significant equity stake, directly holding 313,680 Ironwood shares. The transaction, though considered a negative filing sentiment, is viewed as neutral by equity analysts given it was a planned sale and Silver's continued substantial ownership.
ETFs Investing in Ironwood Pharmaceuticals, Inc. Class A Stocks
This article lists Exchange Traded Funds (ETFs) that hold Ironwood Pharmaceuticals, Inc. (IRWD) Class A stocks, sorted by market value. It provides key details for each ETF, such as issuer, management style, focus, expense ratio, assets under management (AUM), price, and performance metrics, aiming to assist investors in identifying investment opportunities with diversified exposure.
Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:IRWD)
This article provides an overview of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) stock performance, financial actuals, and analyst estimates. It highlights recent stock price movements, future price forecasts from analysts, historical highs and lows, and key financial metrics like market capitalization, revenue, earnings, and EBITDA. The company does not currently pay dividends and its next earnings report is expected on August 6, 2026.
Ronald Silver, PFO, sells $578k in Ironwood Pharma stock By Investing.com
Ronald Silver, Principal Financial Officer and Principal Accounting Officer at IRONWOOD PHARMACEUTICALS INC, sold 127,890 shares of Class A Common Stock for a total of $578,062. This sale was part of a Rule 10b5-1 trading plan. The transactions occurred after Ironwood Pharma shares surged 493% over the past year, with the stock still considered undervalued by InvestingPro.
Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD) Stock Price, News, Quote & History
This page provides detailed stock information for Ironwood Pharmaceuticals, Inc. (IRWD), including its current stock price, recent trading activity, and key financial metrics such as market cap, P/E ratio, and volume. The company is a biotechnology firm specializing in gastrointestinal diseases. The article also includes a collection of recent news and press releases detailing their Q1 and Q2 2026 earnings, FDA approvals for LINZESS, and investor conference participation.
Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (SWB:I76)
This article provides an overview of Ironwood Pharmaceuticals, Inc. Class A (SWB:I76) including its financial actuals, analyst estimates, and key financial metrics. It covers information on stock performance, future earnings forecasts, past revenue, net income, and employee count. The article also clarifies that Ironwood Pharmaceuticals does not pay dividends and offers instructions on how to purchase its stocks.
Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (BX:I76)
This article provides financial actuals and estimates for Ironwood Pharmaceuticals, Inc. Class A (BX:I76), covering income statements, balance sheets, and cash flow data. It includes analyst forecasts, earnings reports, revenue figures, and other financial metrics. The company's stock ticker, next earnings date (August 6, 2026), and recent financial performance are detailed.
I76 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Ironwood Pharmaceuticals, Inc. Class A (I76), including analyst price targets and predictions for 2027. It details earnings, revenue, and net income figures, and answers frequently asked questions about the company's stock, historical prices, and financial reporting.
Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (MUN:I76)
This article provides actuals and estimates for Ironwood Pharmaceuticals, Inc. Class A (MUN:I76), covering financial data, analyst forecasts, and company details. It includes information on earnings, revenue, net income, and dividend policy, as well as an overview of its stock performance history. The article also addresses frequently asked questions about the company's financials and stock trading.
Director Catherine Moukheibir receives 63,481 Ironwood (IRWD) restricted shares
Ironwood Pharmaceuticals director Catherine Moukheibir has received an equity award of 63,481 shares of Class A common stock, granted as restricted stock with no cash cost. These shares will vest in full on the day before the next annual stockholders' meeting, requiring her continued service. Following this grant, Moukheibir directly holds a total of 181,425 shares of Ironwood Class A common stock.
Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan
Ironwood Pharmaceuticals (IRWD) announced that its stockholders approved an amendment to the 2019 Equity Incentive Plan, adding 10 million shares of Class A common stock for future equity-based compensation. This approval occurred at the 2026 Annual Meeting of Stockholders, where directors were also elected and other proposals received strong support. The amendment expands the pool for employee, officer, and director incentives, as detailed in the company's 8-K filing.
Ironwood (IRWD) director Jay Shepard receives 63,481-share restricted stock grant
Ironwood Pharmaceuticals director Jay Shepard has been granted 63,481 restricted Class A common shares as equity compensation, with no cash cost. The grant was made under the company's Second Amended and Restated Non-employee Director Compensation Policy and vests in full before the next calendar year's annual stockholders' meeting. Following this award, Shepard directly holds 235,036 shares of Ironwood Class A common stock.
Ironwood (IRWD) director Marla Kessler receives 63,481-share restricted stock grant
Ironwood Pharmaceuticals director Marla L. Kessler was granted 63,481 shares of Class A Common Stock as restricted stock. This award was part of the company’s non-employee director compensation policy and vests in full before the next annual stockholders' meeting. Following this grant, Kessler now directly holds 229,364 shares of Class A Common Stock.
Ironwood (NASDAQ: IRWD) director awarded restricted stock that vests before next meeting
Ironwood Pharmaceuticals director Alexander J. Denner was awarded restricted Class A Common Stock as non-cash compensation, with two grants on June 15 and June 16, 2026, totaling 67,546 shares. These shares were issued under the company's Non-employee Director Compensation Policy and will vest in full on the date immediately preceding the next annual meeting of stockholders. Following these awards, Denner's direct holdings increased to 323,855 shares.
Ironwood Pharmaceuticals (IRWD) director granted 63,481 restricted shares in latest Form 4
Ironwood Pharmaceuticals director Jon R. Duane was granted 63,481 shares of Class A Common Stock as equity compensation, as disclosed in a recent Form 4 filing. These restricted shares, awarded at $0.00, will vest fully on the day before the next annual stockholders' meeting, increasing his direct holdings to 253,820 shares. This transaction is a routine director equity award rather than an open-market purchase or sale.
Ironwood (NASDAQ: IRWD) director sells shares and receives new stock grant
Ironwood Pharmaceuticals Inc. director Julie McHugh reported both a sale and a grant of Class A Common Stock. She sold 21,571 shares at a weighted average price of $3.73 under a pre-arranged Rule 10b5-1 trading plan and received a grant of 63,481 restricted shares. After these transactions, McHugh directly holds 272,320 shares.
Ironwood Pharmaceuticals (IRWD) director receives 63,481-share grant
Ironwood Pharmaceuticals director Mark G. Currie was granted 63,481 shares of Class A common stock as restricted stock, awarded at no cash cost as part of his director compensation. Following this award, Currie directly holds 676,900 shares of Ironwood common stock. The restricted stock is set to vest in full on the date immediately preceding the next year's annual meeting of stockholders.
IRWD: Apraglutide and LINZESS drive growth, with new trials, debt reduction, and market leadership ahead
Ironwood Pharmaceuticals, Inc. (IRWD) anticipates a strong year with projected net sales growth and debt reduction. The company expects continued strong performance from LINZESS and the advancement of Apraglutide into a new confirmatory trial, positioning it for potential class leadership due to its favorable clinical profile. This outlook was based on insights from the Jefferies Global Healthcare Conference 2026.
Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant
Ironwood Pharmaceuticals (IRWD) has amended a prior report to detail the compensation for Ronald Silver in his new role as interim chief financial officer. He will receive a monthly interim assignment fee of $12,250 and was granted 25,000 restricted stock units (RSUs) on May 19, 2026, which will vest over two years. This compensation structure aims to align his pay with the company's share performance during his interim role.
Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant
Ronald Silver, PFO & PAO of Ironwood Pharmaceuticals Inc. (IRWD), has been granted 25,000 shares of restricted common stock as equity compensation. This award, valued at $0.00 per share, vests in two equal installments on each approximate anniversary of the grant date. Following this transaction, Silver directly holds a total of 441,570 shares of the company's common stock, demonstrating a significant equity stake.
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Ironwood Pharmaceuticals will present data from its LANDMARK survey at Digestive Disease Week® 2026, focusing on healthcare professionals' insights into the burden of total parenteral nutrition for short bowel syndrome patients. The company will also share long-term safety and tolerability data for apraglutide, an investigational drug for SBS, and linaclotide data for other gastrointestinal conditions like IBS-C, CIC, and functional constipation. These presentations aim to deepen the understanding of current management and inform future therapeutic approaches for these challenging conditions.
Armistice reports 15.03M Ironwood stake (NASDAQ: IRWD) in 13G/A
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 15,028,000 shares of Ironwood Pharmaceuticals (NASDAQ: IRWD) Class A common stock, representing 9.22% of the class, as detailed in an Amendment No. 6 to a Schedule 13G filing. Armistice Capital acts as the investment manager for Armistice Capital Master Fund Ltd., which directly holds the shares, and exercises shared voting and dispositive power. The Master Fund explicitly disclaims beneficial ownership through its Investment Management Agreement, as it lacks the ability to vote or dispose of these securities.
Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD
This article provides recent news and financial updates for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), including its stock performance. It compiles various news headlines from May to July 2021, covering topics like investor update calls, clinical trial results, business agreements, and quarterly earnings reports. The news also highlights broader biotech sector developments that impact IRWD.
Renaissance reports 4.90% stake in Ironwood (IRWD)
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation have reported a 4.90% beneficial stake in Ironwood Pharmaceuticals Inc. This stake amounts to 8,061,073 shares of Class A common stock, with both entities holding sole voting and sole dispositive power. The disclosure was made via an Amendment No. 1 to a Schedule 13G/A SEC filing.
Ironwood Pharmaceuticals, Inc. - Class A Common Stock (NQ: IRWD)
This page provides recent news and press releases for Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), highlighting financial results, conference participation, and updates on their therapies and pipeline. Key announcements include strong quarterly results, maintenance of financial guidance, and developments in treatments for short bowel syndrome.
[8-K] IRONWOOD PHARMACEUTICALS INC Reports Material Event
Ironwood Pharmaceuticals (IRWD) announced that its Senior Vice President and Chief Financial Officer, Gregory Martini, will resign effective May 15, 2026. The company stated this resignation is unrelated to any disagreement concerning its financial reporting. Ronald Silver, currently Senior Vice President, Corporate Controller, and Chief Accounting Officer, will assume the role of interim chief financial officer and principal financial officer on the same date, ensuring continuity in financial leadership.
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Ironwood Pharmaceuticals (NASDAQ:IRWD) significantly beat revenue and earnings per share expectations in its latest quarterly report, leading to new forecasts from analysts. While analysts maintained similar revenue and EPS estimates for 2026, the price target for the stock rose by 26% to US$6.10, indicating increased confidence in the business's intrinsic value. The company is also expected to outpace industry growth, with revenues projected to increase 38% annually until the end of 2026.
Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A (IRWD) News, Articles, Events & Latest Updates
This article provides news and updates for Ironwood Pharmaceuticals Inc (IRWD), including recent financial performance and upcoming events. Despite beating Q1 earnings and revenue estimates driven by strong LINZESS sales, the stock experienced a slight dip. The company continues to focus on developing and commercializing therapies for gastrointestinal and rare diseases.
Ironwood Pharmaceuticals (IRWD) Q1 Profit Of US$40.8 Million Tests Bearish Earnings-Decline Narrative
Ironwood Pharmaceuticals (IRWD) reported a Q1 profit of US$40.8 million, challenging a bearish earnings-decline narrative with US$106.5 million in revenue and US$0.25 basic EPS. While bulls point to a profitable trailing twelve-month profile, bears highlight fluctuating quarterly net income, future revenue declines, and concerns about heavy reliance on key products. The company's stock trades at a low P/E compared to peers, with a high debt and negative equity balance sheet which presents a mixed signal for investors.
Ironwood (IRWD) turns loss to profit as LINZESS drives Q1 2026 revenue surge
Ironwood Pharmaceuticals (IRWD) reported a significant financial turnaround in Q1 2026, swinging from a net loss to a profit, primarily driven by a substantial increase in LINZESS revenue. Total revenues surged to $106.5 million from $41.1 million year-over-year, leading to a diluted EPS of $0.24 compared to a loss of $0.23 in the prior year. The company's focus on its GI franchise and advancing apraglutide through clinical development contributed to improved operating income despite ongoing debt obligations.
Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04
This article reports that the price target for Ironwood Pharmaceuticals (IRWD) has been increased by 28.97%, bringing it to $7.04. The content provided is minimal, offering only this specific financial update without further details or analysis.
